Polysarcosine-Functionalized mRNA Lipid Nanoparticles Tailored for Immunotherapy
Pharmaceutics · 01.08.2023 · 15 (8) · 2068
DOI: 10.3390/pharmaceutics15082068 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmaceutics, online erschienen am 01.08.2023. Verfasst von Christoph Wilhelmy und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biopharmaceutics and Pharmaceutical Technology, Johannes Gutenberg University Mainz, 55128 Mainz, Germany. Die Arbeit wurde bisher 51-mal zitiert (Crossref) und nennt 66 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Deutsche Forschungsgemeinschaft, German Research Foundation (DFG).
Abstract (Originalsprache)
Lipid nanoparticles (LNPs) have gained great attention as carriers for mRNA-based therapeutics, finding applications in various indications, extending beyond their recent use in vaccines for infectious diseases. However, many aspects of LNP structure and their effects on efficacy are not well characterized. To further exploit the potential of mRNA therapeutics, better control of the relationship between LNP formulation composition with internal structure and transfection efficiency in vitro is necessary. We compared two well-established ionizable lipids, namely DODMA and MC3, in combination with two helper lipids, DOPE and DOPC, and two polymer-grafted lipids, either with polysarcosine (pSar) or polyethylene glycol (PEG). In addition to standard physicochemical characterization (size, zeta potential, RNA accessibility), small-angle X-ray scattering (SAXS) was used to analyze the structure of the LNPs. To assess biological activity, we performed transfection and cell-binding assays in human peripheral blood mononuclear cells (hPBMCs) using Thy1.1 reporter mRNA and Cy5-labeled mRNA, respectively. With the SAXS measurements, we were able to clearly reveal the effects of substituting the ionizable and helper lipid on the internal structure of the LNPs. In contrast, pSar as stealth moieties affected the LNPs in a different manner, by changing the surface morphology towards higher roughness. pSar LNPs were generally more active, where the highest transfection efficiency was achieved with the LNP formulation composition of MC3/DOPE/pSar. Our study highlights the utility of pSar for improved mRNA LNP products and the importance of pSar as a novel stealth moiety enhancing efficiency in future LNP formulation development. SAXS can provide valuable information for the rational development of such novel formulations by elucidating structural features in different LNP compositions.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Biopharmaceutics and Pharmaceutical Technology, Johannes Gutenberg University Mainz, 55128 Mainz, Germany.
- TRON-Translational Oncology at the University Medical Center of Johannes Gutenberg University gGmbH, 55131 Mainz, Germany.
- European Molecular Biology Laboratory (EMBL) Hamburg Outstation, c/o DESY, 22607 Hamburg, Germany.
- Nanoparticle Process Technology (NPPT), Faculty of Engineering, University of Duisburg-Essen, 47057 Duisburg, Germany.
- BIOSAXS GmbH, 22607 Hamburg, Germany.
- LACDR-Leiden Academic Centre for Drug Research, Leiden University, 2333 Leiden, The Netherlands.
ORCID-Profile: Christoph Wilhelmy, Isabell Sofia Keil, Lukas Uebbing, Martin A Schroer, Heinrich Haas, Mustafa Diken
Förderung
- Deutsche Forschungsgemeinschaft
- German Research Foundation (DFG)
Zitieren
APA
Wilhelmy, C., Keil, I. S., Uebbing, L., Schroer, M. A., Franke, D., Nawroth, T., Barz, M., Sahin, U., Haas, H., Diken, M., & Langguth, P. (2023). Polysarcosine-Functionalized mRNA Lipid Nanoparticles Tailored for Immunotherapy. Pharmaceutics, 15(8), 2068. https://doi.org/10.3390/pharmaceutics15082068
Vancouver
Wilhelmy C, Keil IS, Uebbing L, Schroer MA, Franke D, Nawroth T, et al. Polysarcosine-Functionalized mRNA Lipid Nanoparticles Tailored for Immunotherapy. Pharmaceutics. 2023;15(8):2068. doi:10.3390/pharmaceutics15082068
BibTeX
@article{Wilhelmy2023,
author = {Wilhelmy, Christoph and Keil, Isabell Sofia and Uebbing, Lukas and Schroer, Martin A and Franke, Daniel and Nawroth, Thomas and Barz, Matthias and Sahin, Ugur and Haas, Heinrich and Diken, Mustafa and Langguth, Peter},
title = {Polysarcosine-Functionalized mRNA Lipid Nanoparticles Tailored for Immunotherapy},
journal = {Pharmaceutics},
year = {2023},
volume = {15},
number = {8},
pages = {2068},
doi = {10.3390/pharmaceutics15082068}
}
EUVIMED